OMEROS CORP
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
OMER$17.30-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| · 2024 · 2023 | ||||
| Operating activities: | ||||
| Net loss | $(125,457) | $(108,745) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | |||
| Stock-based compensation expense | 8,067 | 8,959 | ||
| Amortization of discount and issuance costs on convertible notes | 713 | 1,450 | ||
| Depreciation and amortization | 649 | 715 | ||
| Amortization of non-cash interest and issuance costs on long-term debt | 488 | — | ||
| Non-cash interest earned on OMIDRIA contract royalty asset | (12,824) | (11,484) | ||
| Remeasurement of OMIDRIA contract royalty asset | (7,384) | (14,924) | ||
| Accretion on U.S. government treasury bills, net | (4,295) | (7,280) | ||
| Non-cash interest on royalty obligation | (1,553) | — | ||
| Changes in operating assets and liabilities: | ||||
| OMIDRIA contract royalty asset | 29,586 | 29,900 | ||
| Prepaid expenses and other | 1,790 | 876 | ||
| Receivables | 1,702 | 206,343 | ||
| Accounts payable and accrued expense | (11,305) | 3,741 | ||
| Net cash provided by (used in) operating activities | (119,823) | 109,551 | ||
| Investing activities: | ||||
| Proceeds from the sale and maturities of investments | 969,221 | 751,114 | ||
| Purchases of investments | (921,819) | (839,595) | ||
| Purchases of property and equipment | (139) | (308) | ||
| Net cash provided by (used in) investing activities | 47,263 | (88,789) | ||
| Financing activities: | ||||
| Proceeds from sale of future royalties | 115,525 | — | ||
| Proceeds upon exercise of stock options | 52 | 150 | ||
| Cash paid to repurchase 2026 convertible senior notes | (21,179) | — | ||
| Principal payments on OMIDRIA royalty obligation | (15,125) | (854) | ||
| Repurchases of common stock | (11,851) | — | ||
| Principal payments on finance lease obligations | (446) | (427) | ||
| Net cash provided by (used in) financing activities | 66,976 | (1,131) | ||
| Net increase (decrease) in cash and cash equivalents | (5,584) | 19,631 | ||
| Cash and cash equivalents at beginning of period | 7,105 | 11,009 | ||
| Cash and cash equivalents at end of period | $1,521 | $30,640 | ||
| | | | ||
| Supplemental cash flow information | ||||
| Cash paid for interest | $28,122 | $23,801 | ||
| Cash paid (received) for income taxes, net | $(109) | $3,776 | ||
| Equipment acquired under finance lease | $509 | $632 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.